By: Benzinga
UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of Catalysts
Goldman Sachs reduced its rating on Cepheid (NASDAQ: CPHD ) from Buy to Neutral and reduced its price target from $42 to $32. Goldman Sachs commented, "We downgrade shares of CPHD to Neutral from Buy and lower our 6-month price target to $32 ($42 previously) as we believe CPHD
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here